cyrilzakka/clinical-trials huggingface dataset:
Post Exercise Recovery and FST

In this pilot study the focus is to assess the perceived impact of Fascial Stretch Therapy (FST) on post-exercise recovery in University athletes. The objective is to determine if FST can expedite recovery and enhance overall well-being by reducing muscle soreness and fatigue. The FST protocol will be implement by a certified FST level 2 practitioner. Upon completion of the FST intervention athletes will complete a self-assessment questionnaire. The study aims to provide empirical support for FST's efficacy in improving post-exercise recovery and contributing to the health and performance of university athletes.

Purpose: The purpose of this pilot study is to examine the perceived effects of Fascial Stretch Therapy (FST) on post-exercise recovery among university athletes at UBCO. By focusing solely on this aspect, the study aims to provide a nuanced understanding of how FST influences recovery processes in the context of rigorous athletic training.

Hypothesis: We hypothesize that integrating FST into the post-exercise routine of university athletes will result in expedited recovery, manifested through reduced muscle soreness and fatigue. We expect that the tailored FST sessions will contribute positively to the athletes' overall well-being, allowing them to maintain peak performance levels.

Justification: The justification for this study lies in addressing a gap in current research by honing in on the specific impact of FST on post-exercise recovery. As athletes constantly seek methods to optimize their performance, understanding the potential benefits of FST in this context becomes crucial for informed and evidence-based interventions.

Objectives: The primary objective is to assess the efficacy of FST in enhancing post-exercise recovery among university athletes. Specifically, the study aims to analyze the reduction in muscle soreness and fatigue, providing empirical support for the inclusion of FST in athletic recovery programs.

Research Design: This pilot study adopts a mixed methods one group post-test only design to a allow the understanding of perceived FST in enhancing post-exercise recovery. Participants will complete questionnaires and short semi-structured interviews.

Statistical Analysis: This study will employ descriptive statistical analysis for the questionnaire data and thematic analysis for the interview data.

Eligibility Criteria:
Inclusion Criteria:

* Must be an UBCO student athlete who is at least 19 years of age and currently engaged in normal athletic training

Exclusion Criteria:

* Student athletes under 19 years of age or currently have an existing musculoskeletal injury or medical condition preventing you from engaging in normal athletic training.
Haemodynamical Optimization During Brain Surgery

The decision to give fluids perioperatively could be based on methods used to identify preload responsiveness, either invasive or noninvasive estimates of stroke volume variation during mechanical ventilation. This study compares fluid management using invasive measurement SPV/PPV (Aisys GE) and noninvasive haemodynamic measurement (ClarSight, Edwards).

The aim of the study is to optimise fluid management and to reduce perioperative risks during brain surgery. Adequate perioperative management guided by hemodynamic monitoring can help to reduce the risk of complications and thus potentially improve outcomes.

This study compares fluid management algorithms based either on invasive detection of fluid responsiveness using pulse pressure variation (PPV) and systolic pressure variation (SPV) values (Aisys GE monitoring system) in group A, or on noninvasive measurement of haemodynamics (stroke volume variation (SVV), cardiac index (CI) and systemic vascular resistance (SVR) values) (ClearSight, Edwards) in group B.

Eligibility Criteria:
Inclusion Criteria:

* Glasgow Coma scale 15
* ASA Physical Status Classification System I-III
* planed surgery for brain tumor to 5 hours
* postoperative awakening
* sinus rhythm

Exclusion Criteria:

* NYHA III, IV
* BMI over 40 in females and over 35 in men
* awake operation
* postoperative artificial ventilation
A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors

This is an open-label, multicenter study designed to assess the safety, pharmacokinetics, pharmacodynamics, and therapeutic activity of emactuzumab and RO7009789 administered in combination in participants with locally advanced or metastatic solid tumors that are not amenable to standard treatment. This study will be conducted in two parts: a dose-finding stage (Part I) and an expansion stage (Part II).


Eligibility Criteria:
Inclusion Criteria:

* Eastern Cooperative Oncology Group performance status 0 or 1
* Histologically confirmed diagnosis of locally advanced, recurrent, and/or metastatic triple-negative breast cancer, ovarian cancer, gastric cancer, colorectal cancer, pancreatic cancer, melanoma, or mesothelioma
* Radiologically measurable and clinically evaluable disease as per RECIST v1.1
* Life expectancy of greater than or equal to (\>/=) 16 weeks
* Ability to comply with the collection of tumor biopsies; tumors accessible for biopsy
* Adequate bone marrow, liver, cardiac, and renal function

Exclusion Criteria:

* Allergy or hypersensitivity to components of either study drug formulation
* Active or untreated central nervous system (CNS) metastases as determined by computed tomography (CT) or magnetic resonance imaging (MRI) evaluation during screening or prior radiographic assessments. Participants with radiographically stable, asymptomatic, previously irradiated lesions are eligible provided participant is \>/=4 weeks beyond completion of cranial irradiation and \>/=3 weeks off of corticosteroid therapy
* Participants with leptomeningeal disease; metastases to the brain stem, midbrain, pons, medulla, or within 10 millimeters (mm) of the optic apparatus (optic nerves and chiasm)
* History of human immunodeficiency virus (HIV)
* Participants with active hepatitis B, active hepatitis C, or active tuberculosis
* Pregnant or lactating women
Use of Airtime Incentives to Improve Short Message Service Surveys in Colombia and Tanzania

This study evaluates the effect of four different airtime incentive amounts on short message service (SMS) survey cooperation, response, refusal and contact rates, as compared to control group, in Colombia and Tanzania.

Using random digit dialing (RDD) sampling technique, participants were randomized to one of four airtime incentive amounts contingent on them completing the noncommunicable disease risk factor survey. This mobile phone survey will be sent as a short message service (SMS). In SMS surveys, participants use their touch tone key pad to answer written questions. (i.e. If you are male, press 1; If you are female, press 2). This study will be conducted in both Colombia and Tanzania.

Eligibility Criteria:
Inclusion Criteria:

* Access to a mobile phone
* Greater or equal to 18 years of age
* In Colombia, conversant in the Spanish language. In Tanzania, conversant in the Swahili language.

Exclusion Criteria:

* Less than 18 years of age
Comprehensive Study of Duchenne Muscular Dystrophy at Sohag University Hospital

Muscular dystrophies are a heterogenous group of inherited muscular disorders characterized by progressive muscle weakness. Historically, these disorders are difficult to treat. In the last three decades, there is a great progress in molecular and genetic basis of these disorders; early diagnosis is achievable with proper clinical recognition and advanced genetic testing .Duchenne Muscular Dystrophy (DMD) is a neuromuscular muscular X-linked recessive disorders that belong to a group of disorders known as dystrophinopathies. DMD characterized by a progressive degeneration of skeletal muscles, with symptoms that manifest early, at around 3 years, causing loss of ambulation within the 13 years of life, followed by cardiac complication (e.g., dilated cardiomyopathy and arrhythmia) and respiratory disorders, including chronic respiratory failure. The unique medical treatment available is steroid therapy, which appears to prolong walking capacity by at least two years. Thus, besides medical treatment, the physical therapy in multidisciplinary care is imperative for alleviating muscle atrophy, skeletal deformities, and motor function deterioration.


Eligibility Criteria:
Inclusion Criteria:

1. age of onset between 3- and 18-year-old
2. typical clinical manifestation of Duchenne muscular dystrophy
3. clinical manifestation confirmed by specific biochemical analysis or by genetic testing who presented to pediatric department and neurology outpatient clinic during the period of study.

Exclusion Criteria:

1. children with another congenital muscular dystrophy
2. children with other types of myopathies
3. presence of CNS disorders such as brain insult \& spinal muscular atrophy
4. female gender
Tissue K+ in Primary Hyperaldosteronism

Recent human studies found tissue sodium storage in patients with hyperaldosteronism that could be detected non-invasively by 23Na-MRI. Tissue sodium accumulation could be mobilized upon treatment of hyperaldosteronism. Besides, former animal studies applying chemical electrolyte analysis indicate that this aldosterone induced sodium storage might be accompanied by intracellular potassium loss. Wether such an intracellular tissue Potassium loss occurs in vivo in patients with hyperaldosteronism and if this deficiency can be corrected by treatment is unclear. The investigators will employ 39K-MR Imaging at 7Tesla to further assess this hypothesis.

Patients diagnosed with primary hyperaldosteronism will be investigated using 23Na-MRI and 39K-MRI at 7 Tesla to assess tissue sodium and potassium content. Measurements will be conducted before treatment of hyperaldosteronism and three months after adrenal surgery or medical treatment (Spironolactone or Eplerenone). Furthermore, blood pressure, body water distribution (by bioimpedance spectroscopy), serum electrolytes as well as monocyte function will be assessed.

Eligibility Criteria:
Inclusion Criteria:

- Primary Hyperaldosteronism diagnosed according to the endocrinological guidelines (J Clin Endocrinology \& Metabolism, May 2016)

Exclusion Criteria:

* Chronic kidney disease stage 3b and below (estimated GFR \<30 ml/min according to CKD-EPI)
* Acute kidney injury
* Severe congestive heart failure (NYHA III and IV)
* Liver Cirrhosis (Child B and C)
* Pregnancy
* Contraindications for MRI measurements: cardiac Pacemaker, claustrophobia, etc.
PRactice of Ventilation and Adjunctive Therapies in COVID-19 Patients.

PRactice of Ventilation and Adjunctive Therapies in COVID-19 Patients. An observational study of ventilation practice and adjunctive therapies in critically ill, invasively ventilated COVID-19 patients during the first and second surge of COVID-19 in the Netherlands.


Eligibility Criteria:
Inclusion Criteria:

* receiving invasive ventilation or high-flow nasal oxygen for COVID-19 for SARS-CoV-2
* admitted to one of the ICUs of the participating hospitals

Exclusion Criteria:

* none
The PIFBO-study: Person-centred Information to Parents in Paediatric Oncology

The aim of this project is to evaluate a person-centred informational intervention aimed at parents of children with cancer.

The following hypotheses will be tested: an informational intervention emanating from the parents' self-identified needs is associated to decreased illness-related parenting stress, decreased post-traumatic stress symptoms, increased received knowledge, decreased anxiety, decreased depression, increased satisfaction with information, and decreased number of health care contacts in parents.

BACKGROUND

Parents of children with cancer have great information needs and report that these are not always met. Psychosocial suffering such as stress and anxiety is also common in this group.

INTERVENTION

The intervention in this study builds upon the representational approach for patient education. It emanates from Leventhal's theories about illness representation and educational theories about conceptual change. Central elements in the approach are parental choice of information topics of interest, and a thorough assessment of present parental knowledge before information is given. Each parent in the intervention arm gets four sessions with an intervention nurse.

DESIGN AND METHODS

The study comprises a multi-centre randomized controlled trial with two parallel arms with a 1:1 allocation ratio. One arm will receive the intervention and the other standard care according to local routines at each ward. The effect will be measured with validated instrument which are answered on a web platform. Complementary to the quantitative evaluation, we will perform a process evaluation aiming at understanding the change mechanisms, treatment fidelity, dose delivered, contextual factors of importance and how the intervention further could be optimized.

Eligibility Criteria:
Inclusion Criteria:

Being a parent of a child that

1. is diagnosed with a first time occurrence of a malignancy that is curatively treated and
2. was diagnosed two months ago.

   Further parents must be
3. able to talk, read and write Swedish enough to be able to participate without an interpreter.

Exclusion Criteria:

* None specific.
Actovegin 12-Week Treatment Given First Intravenously and Subsequently Orally in Participants With Peripheral Arterial Occlusive Disease Fontaine Stage IIB

The purpose of the study is to evaluate the efficacy and safety of actovegin in participants with peripheral arterial disease (PAD) Fontaine Stage IIB.

The study will enroll approximately 366 participants. Participants will be randomly assigned to one of the two treatment groups in 1:1 ratio:

1. Actovegin
2. Placebo (dummy inactive substance) - this is a tablet/intravenous infusion that looks like the study drug but has no active ingredient

All participants will be asked to take intravenous infusion for 2 weeks followed by oral tablets for 10 weeks.

This multi-center trial will be conducted Russia, Georgia, and Kazakhstan. The overall time to participate in this study is 25 to 26 weeks. Participants will make multiple visits to the clinic, and 12 weeks after last dose of study drug for a follow-up assessment.

Eligibility Criteria:
Inclusion Criteria:

1. Has a history of stable intermittent claudication lasting more than 6 months before Screening.
2. Has a diagnosis of peripheral arterial disease (PAD) (Code I70.2 according to the international classification of diseases-10th revision) Fontaine Stage IIB confirmed by ultrasound color duplex imaging.
3. Has a resting Doppler ankle-brachial index of less than or equal to (\<=) 0.9.
4. Has intermittent claudication with initial claudication distance (ICD) less than (\<) 200 meters.
5. Is not newly diagnosed with PAD and has a history of stable PAD therapy for at least 2 weeks before Screening.

Exclusion Criteria:

1. Has PAD Fontaine Stage III or IV (pain at rest, non-healing ulceration, or gangrene).
2. Has evidence of nonatherosclerotic PAD.
3. Has greater than (\>) 25 percent (%) variability in absolute claudication distance (ACD) based on treadmill testing during the screening period.
4. Has lower extremity arterial reconstruction (surgical or endovascular) or sympathectomy within 3 months before Screening.
5. Is eligible for surgical/interventional reconstruction.
6. Had a myocardial infarction or major cardiac surgery within 3 months before Screening.
7. Has congestive heart failure (New York Heart Association Class III/IV).
8. Has uncontrolled diabetes mellitus (glycosylated hemoglobin \[HbA1c \>9%\]) or diabetic polyneuropathy.
9. Has any other illness that significantly limits exercise capacity or other medical condition, including any psychiatric disorder that limits participation (in the judgement of the investigator).
10. The subject has received any prohibited medication within 14 days before Randomization (Day 1)
11. The subject is undergoing the supervised exercise training program by the time of Screening and is going to continue this program due to its effectiveness.
Comparison of Self-adhering Mesh and Conventional Mesh in Inguinal Hernia Repair.

Inguinal hernia repair coincides with a high rate of postoperative pain, extending to over a year in 10-20% of patients. Although this is of major concern, early postoperative pain also has an important impact on patients and their ability to regain normal work and activities. Since inguinal hernia repair is the most frequently performed operation worldwide, a small reduction in loss of workdays can already have significant impact on financial issues. As for the origin of the pain, it might be the result of local inflammation caused by the mesh material, but also by nerve entrapment due to fixation techniques. The development of a new mesh which enables sutureless fixation, Cousin Biotech® Adhesix™, may overcome pain related to fixation techniques used in the open hernia repair procedure according to Lichtenstein. Furthermore, the Cousin Biotech® Adhesix™ mesh has already been in use in our institutions and surgeons familiarized themselves with the application.

The investigators would like to conduct a multicentre randomised controlled clinical trial to compare the difference in early postoperative pain after unilateral primary inguinal hernia repair in males. The procedures will be performed in day surgery. Early postoperative pain is defined as the pain during the first month, with a special interest in the first two weeks. In addition, the investigators want to measure the possible benefit in terms of time to return to work, daily activities, quality of life, operation length, complications and long term postoperative pain.


Eligibility Criteria:
Inclusion Criteria:

* Male
* Primary, unilateral inguinal hernia
* Age ≥18 years
* Social status: professionally employed
* ASA-score I-III
* Signed informed consent
* Elective surgery

Exclusion Criteria:

* Female
* Bilateral and/or recurrent inguinal hernia
* Femoral or scrotal hernia
* Vasectomy
* Social status: unemployed
* Chronic use of pain medication
* Symptomatic acute hernia (i.e. bowel obstruction, incarceration, strangulation, peritonitis or perforation of bowel contents)
* ASA-score IV or above
* Incapacitated adult or no signed informed consent
* Patient is unable to speak Dutch
Comparison of Neuromuscular Blockade's Monitoring and Clinical Assessment During Cisatracurium Paralysis in Critically Ill Patients

The main objectives of the prolonged resuscitation paralysis are usually adaptation to mechanical ventilation, lower insufflation pressures and cough suppression.

The use of monitoring during the prolonged neuromuscular blockade is the subject of recommendations. Its interest is subject to a recommendation grade B and its use in prevention of overdose is associated with a recommendation of Grade C.

However, many practitioners continue to objectify the depth of neuromuscular blockade and reversal by simple clinical evaluation. This is a subjective estimate of the depth of neuromuscular block.

Resuscitation in several pharmacokinetic parameters are taken into account. First, the drug distribution volume is usually increased in the Intensive Care patient and requires an increase in initial doses to obtain the same pharmacological effect.

Then, unlike a short-term administration, the administration of neuromuscular blocking agents on days causes diffusion in peripheral compartments. Their diffusion coefficients are slower which contributes to the increase of the elimination period after interruption of the administration of curare. There is therefore a risk of residual paralysis.

Secondarily, the curare needs can be influenced by thermoregulation, water and electrolyte disorders and acid-base, administration of certain drugs, the inter- and intra-individual variability and tachyphylaxis (form tolerance of particularly rapid installation during a few close administration, linked to the proliferation of cholinergic receptors).

The value of monitoring neuromuscular blockade in intensive care is the prevention of overdose and in finding the lowest effective dose.


Eligibility Criteria:
Inclusion Criteria:

* Age over 18 years
* Mechanically ventilated patients
* Indication for prescribing curare extended less than 1 day
* Sedation
* Information form waived by family members or surrogates

Exclusion Criteria:

* Pregnancy,
* Curare infusion ongoing
* Neuromuscular disorders
* Dermal alteration
* Allergy to cisatracurium, atracurium, benzene sulfonic acid
* Expected survival of less than 2 days
* Personal or family history of malignant hyperthermia
* No social security
* Patient under enhanced protection
* Patient participating to an other intervention research or participated within 30 days
Phase 1-2 Evaluation of OT-730 Eye Drops in Reducing the Intraocular Pressure in Patients With Ocular Hypertension or Open-Angle Glaucoma

The purpose of this study is to evaluate the safety and potential efficacy of a new drug, OT-730 ophthalmic solution (eye drops), in reducing intraocular pressure in the eyes of patients with open angle glaucoma or ocular hypertension. It will be compared with commercial timolol and placebo eye drops.

Glaucoma is a group of diseases of the eye that can result in irreversible vision loss due to damage to the optic nerve. Elevated intraocular pressure (IOP) is one factor associated with glaucoma. Currently-available medication used to lower IOP includes beta-blocking agents, which can have undesirable side effects on the cardiac and respiratory systems.

The OT-730 ophthalmic solution contains OT-730, a prodrug that, when applied as an eyedrop, metabolizes to OT-705, an active beta blocker. The OT-730 ophthalmic solution is being studied to see how well it lowers IOP in patients with a diagnosis of open angle glaucoma or ocular hypertension. It will be compared with a well known beta blocker, timolol maleate ophthalmic solution, and with a placebo eye drop, in order to assess its ability to lower IOP without the typical side effects of other beta blockers.

Eligibility Criteria:
Inclusion Criteria:

* healthy subjects, 18 to 80 years of age, any gender
* diagnosis of primary open angle, pseudoexfoliative or pigmentary glaucoma or ocular hypertension

Exclusion Criteria:

* have VA worse than 20/200,
* cataract that compromises visualization of fundus,
* history of lack of response to ocular beta blocker therapy,
* uncontrolled intraocular pressure,
* angle closure glaucoma or occludable angles,
* retinal detachment, macular hole, progressive vision loss, any progressive retinal disease or neurologic disease other than glaucoma that is likely to worsen visual field or acuity during the course of the study,
* a history of, or any current condition contraindicated with use of a beta blocker (e.g., chronic obstructive pulmonary disease, bronchial asthma, congestive heart failure, myasthenia gravis, hypoglycemia, bradycardia, etc),
* chronic use of steroids,
* any disease that, in the opinion of the investigator, may put the patient at significant risk,
* taking systemic beta blockers